

# Monthly Market

Newsletter

January 2025

### Thought for the month

The intelligent investor should recognise that market panics can create great prices for good companies and good prices for great companies."

**Benjamin Graham**



# Market Setup

- Market Outlook
- Equity Investment Ideas
- Technical & Derivatives Outlook
- Commodities Market Outlook
- Advisory Products

## Benchmark Indices

Index	Dec 24	MoM(%)	YoY(%)
Sensex	78,139	-2.1%	8.2%
Nifty	23,644	-2.0%	8.8%

## Economic Pulse

Key Indicators	Curr. Month	Prev. Month
IIP	3.50%	3.10%
CPI	5.48%	6.21%

## Key Highlights

- Nifty ends 2024 with 9% gains – 9th straight year of gains
- India GDP growth projected at 6.4% in FY25
- Key Events: Q3 earnings, Trump Presidency, Union Budget



# Siddhartha Khemka

Sr. Group Vice President  
Head - Retail Research

Equity markets ended 2024 on a positive note, with Nifty gains of 8.8% – its 9th consecutive year of positive returns. The last three years have been remarkable, as domestic markets have navigated through global hurdles, all while facing significant selling from FIIs. Mid & Smallcaps both have outperformed in 2024 with gains of 24% each.

2025 is likely to start on a consolidation mode, while a recovery could take place in the second half. The start of rate cut cycle by RBI, ongoing US rate cut trend, and the global policy post Donald Trump taking over as US President in Jan'25 would influence the market direction. Additionally, the Union Budget in Feb'25 will offer important insights over the government spending trends. With a fragile global economic environment, mixed macroeconomic factors at home, and the spread of a new virus in China (HMPV), the market is expected to remain in consolidation mode in the near term.

Nifty climbed to an all-time high of 26,277 in September 2024 led by continued market momentum and strong domestic flows. However, it subsequently corrected by almost 11% from this peak. This led the Nifty valuation to drop to ~19.5x 1-year forward P/E, below its 10-year average of 20.5x. We expect earnings to gain momentum from H2, and deliver a 16% growth in FY26 after a subdued 5% growth in FY25.

Moreover, the market correction and the moderation in valuations offer an opportunity to add selective bottom-up stock ideas. We remain optimistic about the long-term trend, given the strength of corporate India's balance sheets and the prospects for robust, profitable growth.

In terms of sectors, we are positive on BFSI supported by comfortable valuations and improving business growth. We expect a revival in the export sectors (IT, Pharma) with the INR hitting an all time low and demand recovery in key regions. Consumer discretionary segments like jewellery, real estate and travel & tourism are likely to see sustained spending. Niche themes like Capital Market, EMS, Digital e-commerce would continue to report strong earnings growth.

# Equity Investment Ideas

**HCL Tech**

**CMP :** 1,932

**TARGET :** 2,400

**BUY**

- HCLT anticipates 3.7% QoQ CC growth, supported by seasonal tailwinds, strong deal wins, and maintaining FY25 growth guidance of 3.5%-5%.
- Strategic investments in GenAI and data/SAP modernization position HCLT for recovery, with an expected USD revenue CAGR of 8.4% over FY25-27
- Margins are set to improve by 50bps QoQ, with further expansion to 18.9% by FY26, driven by operational efficiencies and software growth.

- IPCA is poised for a strong turnaround, driven by a revival in its US business through new product launches, stable pricing, and the integration of Unichem.
- Its ex-US markets, including Australia, New Zealand, and Europe, are set to grow with enhanced offerings. Domestically, the company is expanding into fast-growing therapies like cosme-to-dermatology and orthopedics, while improving MR productivity.
- Unichem synergies, operational efficiency, and a strong domestic formulation business are expected to drive a 27% earnings CAGR and ~16% return ratio over FY24-27.

**IPCA Labs**

**CMP :** 1,694

**TARGET :** 1970

**BUY**

**Max Health**

**CMP :** 1,203

**TARGET :** 1,380

**BUY**

- Max Healthcare plans to increase its total bed capacity by 84% (3,332 beds) by FY27 through INR73b capex, with 70% brownfield expansion ensuring efficient utilization of existing infrastructure.
- Beyond FY27, it aims to add ~4,500 beds to increase its capacity to over 11,000 beds, ensuring sustained growth, scale advantages, & robust long-term profitability through strategic expansions.
- We expect revenue/EBITDA/PAT CAGR of 18.4%/16.2%/20.5% over FY25-27, driven by brownfield expansions, enhanced operating leverage, and quicker EBITDA breakeven for new beds.

- Anant Raj is diversifying into high-growth data centres & higher-margin cloud services (IaaS) through partnership with Orange. Cloud capacity is projected to rise to 25% by FY32 enhancing profitability.
- Residential seg. remains strong, with 14msf of deliveries expected by FY30, generating a cumulative NOPAT of INR85.1b. Robust pre-sales, collections, and operational cash flows is expected to drive growth.
- It's shift to data centres leverages India's digital transformation & data localization trends. With 300MW capacity planned over the next 4-5 years, ARCP aims to enhance execution speed & cost efficiency.

**Anant Raj**

**CMP:** 935

**TARGET:** 1,100

**BUY**



# Technical & Derivatives Outlook



- Nifty index started December on a flattish note and buying interest was seen for 24850 zones but witnessed some profit booking thereafter. It fell steeply by 1320 points followed by some stability towards the end of the month. On the sectoral front we have witnessed buying interest in Pharma, Realty and IT names while weakness in Energy, Metal, CPSE and FMCG sector.
- Technically, index is respecting its upwards sloping channel on monthly scale connecting the swing lows of 7511, 15183, 16828, 18837 and 21281 zones. Nifty has formed a bearish candle with longer upper shadow indicating pressure at higher zones. Now Nifty has to hold above 24000 zones for bounce towards 24800 and 25200 zones with immediate support near 23750 and 23450 zones.




# Derivative Strategy

## **NIFTY: Iron Butterfly spread : Dec Series**

- BUY 1 LOT OF 24000 CALL
- SELL 1 LOT OF 24400 CALL
- SELL 1 LOT OF 24700 CALL

Margin Required : Rs.60,000  
 Net Premium Paid : 90 Points (Rs.2250)  
 Risk Scenario 1 : 90 Points (Rs.2250)  
 Risk Scenario 2 : Unlimited risk above 25010 levels  
 Max Profit: 310 Points ( Rs.7750)  
 Lot size : 25  
 Profit if it remains in between 24090 to 25010 zones



# Rationale


- Nifty index is consolidating on weekly scale from last few weeks as it got stuck in wider range.
- On weekly scale multiple supports are intact at lower zones but selling pressure is seen at higher zones which suggests capped upside
- Call OI is at 24000 then 24500 strike while Put OI is seen at 23500 strike.
- Thus suggesting Bull Call Ladder Spread to play the upside swing but with capped upside

# Commodities & Currency Outlook

- Gold marked an all-time high in 2024, posting gains of ~27% in 2024 on COMEX.
- Bullions role as a geopolitical hedge significantly boosted its performance.
- In 2024, the US Fed cut rates by 100bps but maintained a cautious stance, limiting gold's upside
- The Fed is expected to cut rates by another 100bps in 2025, with inflation softening yet staying above target.
- Higher rates from a policy reversal could challenge gold prices.
- Despite volatility, the dollar index found support later in the year as a safe-haven currency.
- Central bank and investor purchases balanced out weaker consumer demand
- Trade wars, inflationary pressures, and risk-on flows may change growth outlook.
- Slower growth forecasts may provide a price floor, reinforcing gold's resilience
- Domestic Gold imports and ETF flows were significant in 2024, similar trend next could continue to support market sentiment
- SPDR holdings also witnessed inflow towards the end of last year.
- Trump's potential second term poses key uncertainties for global growth, influencing gold prices.
- If growth meets expectations, gold may trade within the late-2024 range, with potential for upside.
- Lower rates or heightened geopolitical risks will likely enhance gold's performance.
- Stronger central bank demand or worsening financial conditions could drive further upside for gold.
- Gold prices may see directional cues in Q1 2025 following Trump's inauguration, providing accumulation opportunities
- We could witness lot of 'if's' and 'but's' providing higher swings this year, with second half possibly becoming more actionable for bullion
- A "buy on dips" strategy is recommended to capitalize on potential price fluctuations from a longer term perspective.
- Click on the link to view our detailed Review 2024-Preview 2025, annual report: <https://ftp.motilaloswal.com/emailer/commodity/Review'24 Preview'25.pdf>



# Commodities & Currency Outlook





# Intelligent Advisory Portfolios (IAP)

IAP offers a diverse range of pre-packaged equity portfolios advised by Registered Investment Advisors (RIAs), ideal for both active and passive investors. These portfolios are curated & monitored by the RIAs and follow strict rules & parameters to manage your investments.

## Benefits of IAP



Diversified option to choose from ROBO Managed Investment Products to process driven products with the advisor overlay



Flexible investment modes with option to choose Lump Sum & SIP



24X7 Portfolio tracking



Option to choose from Dynamic or Static portfolios



Choice to execute advice

## Product offerings in Intelligent Advisory Portfolios

- Alpha Bluechip
- Buoyant Opportunities
- NS Industry Champ
- NS 5Tx5T
- PRIME
- Alpha next
- Alpha Masters of the Street
- Abakkus Smart Flexi Cap
- Trend Investing
- NS MID & Smallcap
- NS Ethical
- Zodiac
- AAA EBO



The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL), National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishView/Litigation.aspx>. MOFSL, its associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- a) received any compensation/other benefits from the subject company of this report
- b) managed or co-managed public offering of securities from subject company of this research report,
- c) received compensation for investment banking or merchant banking or brokerage services from subject company of this research report,
- d) received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report.
- MOFSL and its associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have:

- a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.
- (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Disclosure of Interest Statement

Analyst ownership of the stock No

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule I to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For US:

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker-dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited, ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered/qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore, as per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph II of First Schedule of Financial Advisers Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(i) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

This report is intended for distribution to Retail Investors.

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions - including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai- 400025; Tel No.: 022 - 71934200 / 71934263; [www.motilaloswal.com](http://www.motilaloswal.com). Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No.: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: [na@motilaloswal.com](mailto:na@motilaloswal.com). Contact No.: 022- 40548085.

Grievance Redressal Cell:	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	<a href="mailto:query@motilaloswal.com">query@motilaloswal.com</a>
Ms. Kumud Upadhyay	022 40548082	<a href="mailto:servicehead@motilaloswal.com">servicehead@motilaloswal.com</a>
Mr. Ajay Menon	022 40548083	<a href="mailto:am@motilaloswal.com">am@motilaloswal.com</a>

Registration details of group entities: Motilal Oswal Financial Services Ltd. (MOFSL): IN2000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN : 146822. IRDA Corporate Agent - CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/clarification may write to [query@motilaloswal.com](mailto:query@motilaloswal.com). In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to [grievances@motilaloswal.com](mailto:grievances@motilaloswal.com) for DP to [dp.grievances@motilaloswal.com](mailto:dp.grievances@motilaloswal.com).